Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 372

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 372
---
2024 as compared to $0.4 million for the nine months ended September 30, 2023 due to an increase in loans made to the Iris entity.

Net cash used in investing activities was $0.8 million for the year ended December 31, 2023 as compared to $0 for the year ended December 31, 2022 due to the loans to the Iris entity.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2024 of $3.2 million resulted from borrowings from Valetudo, Prophase and Hana of $0.8 million, $1.6 million and $0.8 million, respectively. Net cash used in financing activities of $1.7 million for the nine months ended September 30, 2023 was from $2.0 million from borrowings with Valetudo, offset by $3.7 million of repayments for two short-term loans.

Net cash used in financing activities for the year ended December 31, 2023 of $0.5 million resulted from loan payments made on the Ewon Loan and Prophase Loans of $3.9 million offset by $3.4 million received in short-term loans from Valetudo and Ewon. Net cash provided by financing activities for the year ended December 31, 2022 of $5.9 million was primarily due to $4.2 million received from Ewon’s membership purchase and proceeds of short-term debt borrowings of $7.1 million; offset by $3.3 million of repayment of the loan from TDT, $1.4 million of repayments for two related party short-term loans, and $0.7 million from repurchasing Class A member units.

#### Contractual Obligations and Other Commitments
As of September 30, 2024, we have contractual obligations related to the Feelux Bonds of $10.0 million issued in 2018, and related interest of 1% per annum compounded annually which is expected to be settled through the issuance of ParentCo common shares upon the closing of the Business Combination, our non-interest bearing loan from Car-Tcellkor of $0.8 million due in May 2023, our non-interest bearing Valetudo Loan of $0.7 million, issued in December 2022 which was due in June 2023, the $2.0 million Ewon Loan issued in December 2022, which was due